Objective: To determine the pharmacokinetics characteristics of mestinon-phospholipid complex (PBPLC) in rats.
Methods: This study adopted a single-dose, randomized, open-label, two-period crossover trial design. Twelve healthy rats were randomly divided into two groups. One group was orally administered with mestinon-phospholipid complex, and the other group was orally administered with reference mestinon solution (1.5 mg/kg of mestinon). The plasma concentrations of the drugs in ophthalmic vein bloods were determined using HPLC. The pharmacokinetic parameters were calculated with the aid of DAS2.1.1 software.
Results: Pharmacokinetic parameters of mestinon-phospholipid complex were Tmax 2 h, Cmax 22.79 microg x min/mL and AUC(0-infinity) 7128.21 microg x min/mL, which were different from those of free mestinon--Tmax, 2 h, Cmax 6.00 microg/mL and AUC(0-infinity) 1772.36 microg x min/mL. The relative bioavailability of mestinon-phospholipid complex was 410.98% of free mestinon.
Conclusion: The oral bioavailability of mestinon increases remarkably when administered as mestinon-phospholipid complex.
Download full-text PDF |
Source |
---|
Sichuan Da Xue Xue Bao Yi Xue Ban
November 2012
Medicine Engineering Research Center in University, Chongqing Key Laboratory of Biochemical & Molecular Pharmacology, Chongqing Medical University, Chongqing 400016, China.
Objective: To determine the pharmacokinetics characteristics of mestinon-phospholipid complex (PBPLC) in rats.
Methods: This study adopted a single-dose, randomized, open-label, two-period crossover trial design. Twelve healthy rats were randomly divided into two groups.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!